The antiretroviral treatment (ART) has significantly reduced the number of new HIV/AIDS infections and related deaths. However, cases of immunovirological discordance (IVD) are found in various locations. The objective of this study was to determine the profile of People living with HIV (PLHIV) with IVD and to identify associated factors. We conducted a cross-sectional study based on the records of PLHIV under ART for at least 6 months, followed at Hôpital de Jour Donka from 2015 to 2017, and having both viral load (CV) and CD4 T-cell count. Prevalence of IVD was 34.57%, with 23.87% for immunological discordance (ID) and 10.7% for virological discordance (VD). Females were predominant (66.26%), and male gender influenced IVD with a statistically significant difference (p = 0.006) and was associated with VD (p = 0.007). The average age was 38.77 ± 11.30 years. PLHIV were classified at WHO stages 3 and 4 (86.01%). The median initial haemoglobin level was 11.5 g/L [3.2 - 12]. The mean initial CD4 T-cell count was 272.84 cells/mm3 ± 201.6. The median initial viral load (VL) was 147,337 copies/mL [1092 - 31,675,000]. The initial CD4 T-cell count < 200 cells/mm3 was associated with IVD with a statistically significant difference (p = 0.0009) and correlated with ID (p = 0.000). Prurigo was associated with IVD with a statistically significant difference (p = 0.003). Cerebral toxoplasmosis was not associated with IVD but was associated with ID (p = 0.04). This study allowed us to describe the profile of PLHIV with IVD. The main associated factors were male gender, initial CD4 T-cell count < 200 cells/mm3, toxoplasmosis, prurigo, and herpes zoster.
References
[1]
Arici, C., Ripamonti, D., Ravasio, V., Maggiolo, F., Rizzi, M., Finazzi, M.G., et al. (2001) Long-Term Clinical Benefit after Highly Active Antiretroviral Therapy in Advanced HIV-1 Infection, Even in Patients without Immune Reconstitution. International Journal of STD & AIDS, 12, 573-581. https://doi.org/10.1258/0956462011923741
[2]
Bazié, W.W., Somé, D.Y., Traoré, I.T., Sanon, A., Konaté, I., Tassembedo, S., et al. (2022) Immunovirological Discordance among Female Sex Workers Who Start Antiretroviral Therapy in Burkina Faso. BMC Infectious Diseases, 22, Article No. 117. https://doi.org/10.1186/s12879-022-07109-8
[3]
Zoufaly, A., Cozzi-Lepri, A., Reekie, J., Kirk, O., Lundgren, J., Reiss, P., et al. (2014) Immuno-Virological Discordance and the Risk of Non-AIDS and AIDS Events in a Large Observational Cohort of HIV-Patients in Europe. PLOS ONE, 9, e87160. https://doi.org/10.1371/journal.pone.0087160
[4]
Lapadula, G., Cozzi-Lepri, A., Marchetti, G., Antinori, A., Chiodera, A., Nicastri, E., et al. (2013) Risk of Clinical Progression among Patients with Immunological Nonresponse despite Virological Suppression after Combination Antiretroviral Treatment. AIDS, 27, 769-779. https://doi.org/10.1097/QAD.0b013e32835cb747
[5]
Kacker, M., Vashisht, R. and Menon, A. (2023) Immunovirological Discordance among People Living with Human Immunodeficiency Virus at a Center in Western India: A Retrospective Study. Indian Journal of Sexually Transmitted Diseases and AIDS,44, 15-19. https://doi.org/10.4103/ijstd.ijstd_121_22
[6]
Piketty, C., Weiss, L., Thomas, F., Mohamed, A.S., Belec, L. and Kazatchkine, M.D. (2001) Long-Term Clinical Outcome of Human Immunodeficiency Virus-Infected Patients with Discordant Immunologic and Virologic Responses to a Protease Inhibitor-Containing Regimen. The Journal of Infectious Diseases, 183, 1328-1335. https://doi.org/10.1086/319861
[7]
Moore, D.M., Hogg, R.S., Yip, B., Wood, E., Tyndall, M., Braitstein, P., et al. (2005) Discordant Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy Are Associated with Increased Mortality and Poor Adherence to Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes, 40, 288-293. https://doi.org/10.1097/01.qai.0000182847.38098.d1
[8]
Anude, C.J., Eze, E., Onyegbutulem, H.C., Charurat, M., Etiebet, M.-A., Ajayi, S., et al. (2013) Immuno-Virologic Outcomes and Immuno-Virologic Discordance among Adults Alive and on Anti-Retroviral Therapy at 12 Months in Nigeria. BMC Infectious Diseases, 13, Article No. 113. https://doi.org/10.1186/1471-2334-13-113
[9]
Kaufmann, G.R., Bloch, M., Finlayson, R., Zaunders, J., Smith, D. and Cooper, D.A. (2002) The Extent of HIV-1-Related Immunodeficiency and Age Predict the Long-Term CD4 T Lymphocyte Response to Potent Antiretroviral Therapy. AIDS, 16, 359-367. https://doi.org/10.1097/00002030-200202150-00007
[10]
Gilson, R., Man, S., Copas, A., Rider, A., Forsyth, S., Hill, T., et al. (2010) Discordant Responses on Starting Highly Active Antiretroviral Therapy: Suboptimal CD4 Increases despite Early Viral Suppression in the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Medicine, 11, 152-160. https://doi.org/10.1111/j.1468-1293.2009.00755.x
[11]
Aiuti, F. and Mezzaroma, I. (2006) Failure to Reconstitute CD4 T-Cells despite Suppression of HIV Replication under HAART. AIDS Reviews, 8, 88-97.
[12]
Ouedraogo, S.M., Zoungrana, J., Sondo, K.A., Kyelem, C.G., Koussé, S., Hema, A., et al. (2015) [Immuno-Virologic Dissociation in Patients Infected by HIV-1 under Antiretroviral Treatment at the Day Hospital of Bobo-Dioulasso from 2008 to 2012 (Burkina Faso)]. Le Mali medical, 30, 58-64.
[13]
Kà., D., Manga, N.M., Ngom-Guéye, N.F., Ndiaga, D., Diop, M., Cisse-Diallo, V.M.P., et al. (2017) Facteurs associés à la dissociation immunovirologique chez les patients infectés par le VIH-1 sous traitement antirétroviral hautement actif au Centre de Traitement Ambulatoire (CTA) de Dakar. Pan African Medical Journal,27, Article 16. https://doi.org/10.11604/pamj.2017.27.16.9811
[14]
Wandeler, G., Gsponer, T., Mulenga, L., Garone, D., Wood, R., Maskew, M., et al. (2013) Zidovudine Impairs Immunological Recovery on First-Line Antiretroviral Therapy: Collaborative Analysis of Cohort Studies in Southern Africa. AIDS, 27, 2225-2232. https://doi.org/10.1097/QAD.0b013e328362d887
[15]
Marziali, M., De Santis, W., Carello, R., Leti, W., Esposito, A., Isgrò, A., et al. (2006) T-Cell Homeostasis Alteration in HIV-1 Infected Subjects with Low CD4 T-Cell Count despite Undetectable Virus Load during HAART. AIDS, 20, 2033-2041. https://doi.org/10.1097/01.aids.0000247588.69438.fd
[16]
Casotti, J.A.S., Passos, L.N., De Oliveira, F.J.P. and Cerutti, J.R.C. (2011) Prevalence of Discordant Immunologic and Virologic Responses in Patients with AIDS under Antiretroviral Therapy in a Specialized Care Center in Brazil. Revista do Instituto de Medicina Tropical de São Paulo, 53, 301-307. https://doi.org/10.1590/S0036-46652011000600001
[17]
Massaly, A. (2017) Prévalence et facteurs associés à la dissociation immuno-virologique chez des patients vivant avec le VIH suivis à l’Hôpital de Mbour. Ph.D. Thesis, UniversitéCheikh Anta Diop de Dakar, Dakar. http://bibnum.ucad.sn/viewer.php?c=mmoires&d=memm_2017_0383
[18]
Tan, R., Westfall, A.O., Willig, J.H., Mugavero, M.J., Saag, M.S., Kaslow, R.A., et al. (2008) Clinical Outcome of HIV-Infected Antiretroviral-Naive Patients with Discordant Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes, 47, 553-558. https://doi.org/10.1097/QAI.0b013e31816856c5
[19]
Kone, F., D’Aquin Toni, T., Ouassa, T., Menan, H., Ebegui, D., Diallo, K., et al. (2019) Mesure de l’ARN VIH-1 et du taux de lymphocytes TCD4 dans le suivi du traitement antirétroviral de patients infectés par le VIH en Côte d’Ivoire. International Journal of Biological and Chemical Sciences, 13, 1343-1353. https://doi.org/10.4314/ijbcs.v13i3.11
[20]
Penot, P., Héma, A., Bado, G., Kaboré, F., Soré, I., Sombié, D., et al. (2014) The Vulnerability of Men to Virologic Failure during Antiretroviral Therapy in a Public Routine Clinic in Burkina Faso. Journal of the International AIDS Society, 17, Article 18646. https://doi.org/10.7448/IAS.17.1.18646
[21]
Vih.org (2019) Santé, réduction des risques et usages de drogues No62/ 1ertrimestre 2011. http://vih.org/documents/swaps62.pdf
[22]
Aubry, P. and Gaüzère, B.-A. (2024) Infection par le VIH et tropiques. http://medecinetropicale.free.fr/cours/sida_tropical.pdf
[23]
Kayigamba, F.R., Franke, M.F., Bakker, M.I., Rodriguez, C.A., Bagiruwigize, E., Wit, F.W., et al. (2016) Discordant Treatment Responses to Combination Antiretroviral Therapy in Rwanda: A Prospective Cohort Study. PLOS ONE, 11, e0159446. https://doi.org/10.1371/journal.pone.0159446
[24]
Smith, C.J., Sabin, C.A., Youle, M.S., Kinloch-De Loes, S., Lampe, F.C., Madge, S., et al. (2004) Factors Influencing Increases in CD4 Cell Counts of HIV-Positive Persons Receiving Long-Term Highly Active Antiretroviral Therapy. The Journal of Infectious Diseases,190, 1860-1868. https://doi.org/10.1086/425075
[25]
Pinzone, M.R., Di Rosa, M., Cacopardo, B. and Nunnari, G. (2012) HIV RNA Suppression and Immune Restoration: Can We Do Better? Journal of Immunology Research, 2012, Article ID: 515962. https://doi.org/10.1155/2012/515962
[26]
Kilaru, K., Kumar, A., Sippy, N., Carter, A.O. and Roach, T.C. (2006) Immunological and Virological Responses to Highly Active Antiretroviral Therapy in a Non-Clinical Trial Setting in a Developing Caribbean Country. HIV Medicine, 7, 99-104. https://doi.org/10.1111/j.1468-1293.2006.00347.x
[27]
Grabar, S., et al. (2000) Clinical Outcome of Patients with HIV-1 Infection According to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy. Annals of Internal Medicine, 133, 401-410. https://doi.org/10.7326/0003-4819-133-6-200009190-00007
[28]
Ndongue-Sarr, M., Batista, G., Ngom-Guéye, N.F., Ndour, C.T., et al. (2013) Etude comparative des PVVIH sous trithérapie avec une restauration immunitaire optimale et cas de dissociation immuno-virologique. Médecine et Maladies Infectieuses, 43, 11.
